NICE Diabetes Revolution, EU Device JCAs, Clinical Trial Acceleration

Episode 24 — 07 June 2026 NICE's revolutionary diabetes guideline makes SGLT-2 inhibitors first-line therapy while EU HTA regulation expands to high-risk medical devices. FDA accelerated approvals surge and EU clinical trial acceleration shows early progress toward 2030 targets. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast

Transcript

SPEAKER_00 0:00

Welcome to Access Brief, the daily AI podcast on Qior, HTA, and market access. I'm Marcus with Sarah. Today, NICE's radical diabetes prescribing transformation, EU device JCA's launching, and FDA's accelerated approval surge. Let's get into it.

SPEAKER_01 0:16

The February 2026. NICE NG28 update is the biggest diabetes prescribing shift we've seen. SGLT2 inhibitors are now first-line therapy with metformin for all type 2 diabetes patients, regardless of comorbidities. NICE projects, 17,000 deaths prevented over three years.

SPEAKER_00 0:35

This is evidence-driven prescribing at its best. Moving from glycemic control primacy to cardiovascular and renal protection makes clinical sense. Seven tailored pathways for specific comorbidities, early onset diabetes, heart failure, chronic kidney disease, frailty. The evidence base for SGLT2 cardioprotection is rock solid.

SPEAKER_01 0:58

But Marcus, this is also a massive commercial restructuring disguised as clinical guidance. We're essentially mandating dual therapy as standard, doubling drug spend per patient from day one. Yes, the long-term outcomes look favorable, but the budget impact modeling here must be extraordinary.

SPEAKER_00 1:15

You're focusing on acquisition cost, not total cost of care. If we prevent 17,000 deaths, we're also preventing hundreds of thousands of hospitalizations, dialysis initiations, amputations. The downstream savings dwarf the upfront drug costs.

SPEAKER_01 1:28

That's assuming perfect adherence and real-world effectiveness, matching trial data. We're extrapolating trial populations to entire type 2 diabetes cohorts. The health economic modeling is aggressive.

SPEAKER_00 1:40

Moving to the EU HTA regulations device expansion, June 2026 brings the first JCAs for Class 2B and 3 devices, plus Class D IVDs, approximately 50 JCAs for medicines, plus five device JCAs in the 2026 work program.

SPEAKER_01 1:57

The operational constraints are already showing. Joint scientific consultation slots capped at 17 for 2026, 8, 12 for medicines, 2, 5 for devices. Demand exceeds capacity before we've even hit steady state. This is rationing scientific advice.

SPEAKER_00 2:13

It's capacity planning reality. The European Commission is managing a staged rollout rather than overwhelming the system. Better controlled expansion than collapse under demand.

SPEAKER_01 2:23

But we're creating artificial scarcity in scientific advice just as device manufacturers need guidance most. The first device JCAs will set precedents for methodology, assessment scope, clinical endpoints. Limited consultation access at this critical juncture is strategically problematic.

SPEAKER_00 2:41

The EU Clinical Trial Progress Report shows tangible acceleration. 19 additional multinational trials beyond historical averages, 40.5% recruiting within 200 days toward the 66% target by 2030.

SPEAKER_01 2:56

Early momentum, but let's be realistic about the trajectory. We need 500 extra trials by 2030. 19 additional in Q1 puts us well behind the linear progression needed. And 40.5% recruitment within 200 days is still under half of trials meeting reasonable timelines.

SPEAKER_00 3:14

You're expecting linear progress on a transformation that requires infrastructure changes, regulatory harmonization, investigator training, early indicators matter more than absolute numbers.

SPEAKER_01 3:26

Finally, May 2026's FDA accelerated approvals deserve attention. Son rotoclax for mantle cell lymphoma, all oral AML regimen with decidabine, cetazuridyne plus Venetaclax, V Pedigesterin for ESR 1 mutated breast cancer, plus the June 2nd draft guidance accelerating cell and gene therapies.

SPEAKER_00 3:45

The FDA is clearly committed to expedited pathways for innovation, but accelerated approvals create downstream HTA challenges. Payers need robust evidence for coverage decisions, and accelerated pathways often mean limited real-world data at launch.

SPEAKER_01 4:01

Exactly the tension we're seeing globally.